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REAL-WORLD TRENDS IN THE DIAGNOSIS AND ASSESSMENT OF 
RHEUMATOID ARTHRITIS (RA) AMONG RHEUMATOLOGISTS IN  
THE UNITED STATES
DiBonaventura M1, Roy S2, Ertl J1, Cifaldi M2
1KantarHealth, New York, NY, USA, 2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: Diagnosis and management of rheumatoid arthritis (RA) have changed 
dramatically during the last several years, with the emergence of new guidelines, treat-
ment options, and diagnostic tests. These involve varying degrees of complexity, and 
place demands on time and resources in routine clinical practice. The aim of this study 
was to assess current trends in RA diagnosis and assessment practices among US 
rheumatologists. METHODS: A sample of rheumatologists (N = 86) was surveyed 
online through an actively-managed Internet panel. Physicians were asked which 
diagnostic and disease severity measures they were aware of, and how often they used 
those measures—for both diagnosis and disease severity assessment. RESULTS: Physi-
cians were mostly male (n = 62, 72.1%) and practiced in suburban areas (n = 44, 
51.2%). The mean number of years in practice (post-residency) was 16.3, and the 
mean number of RA patients seen per month was 136.5. Physicians treated more RA 
patients with disease-modifying antirheumatic drugs (DMARDs) and biologics than 
with non-steroidal anti-inﬂammatory drugs (NSAIDS), COX-2 inhibitors, and corti-
costeroids. The most common diagnostic measure was anti-cyclic citrullinated peptide 
(anti-CCP) assays (97.7%). The most common disease assessments were swollen joint 
count (88.4%), tender joint count (87.2%), erythrocyte sedimentation rate (81.4%), 
C-reactive protein (77.9%), patient’s assessment of physical function (75.6%), and 
patient’s assessment of pain (74.4%). 54 physicians (62.7%) reported employing 
HRQOL questionnaires to assess patients’ well-being, the Health Assessment Ques-
tionnaire (HAQ) being the most common (43.4%). CONCLUSIONS: Though rela-
tively new, anti-CCP assays were employed by almost all physicians for RA diagnoses. 
While other serum markers were often used for diagnosis, they were less likely to be 
used for disease severity assessment versus physicians’ and patients’ assessments of 
symptoms and physical function. Although a majority of physicians used HRQOL 
measures, the opportunity exists for further adoption and standardization of such 
measures to facilitate better management of RA.
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TWO YEAR MAINTENANCE INFLIXIMAB DOSING AND 
ADMINISTRATION PATTERNS IN PATIENTS WITH RHEUMATOID 
ARTHRITIS
Bailey R1, Bolge S1, Ernst FR2, Johnson B2, McKenzie RS1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Premier, Inc, Charlotte, NC, 
USA
OBJECTIVES: Food and Drug Administration (FDA)-approved prescribing informa-
tion recommends inﬂiximab (IFX) administration at 0, 2, 6 and every 8 weeks with 
potential dose increase based on patient response for patients with RA. Minimal real 
world dosing data are available in this population. This study evaluated IFX dosing 
patterns in patients with rheumatoid arthritis (RA) treated in the outpatient hospital 
setting. METHODS: A retrospective longitudinal analysis using the Premier Perspec-
tiveTM Database, a United States-based hospital database, was conducted. Inclusion 
criteria were an outpatient hospital discharge RA diagnosis (ICD-9 code 714.xx) 
between July 1, 2000 and December 31, 2008, IFX-naïve, and ≥3 IFX doses within 
≤56 days of the index infusion. Exclusion criteria included patients with other selected 
inﬂammatory diseases. Treatment duration was deﬁned as the time between the index 
and last IFX dose. The 4th through 15th IFX doses were analyzed representing the ﬁrst 
2 years of IFX maintenance treatment. RESULTS: A total of 2185 patients with RA 
receiving IFX were identiﬁed. Mean (SD) age was 60.3 (14.0) years; 79.0% were 
female. Mean (SD) treatment duration was 465 (459) days. Patients received a mean 
(SD) of 9.9 (8.8) IFX administrations. Mean (SD) index IFX dose was 338.2 (156.8) 
mg. Mean (SD) maintenance IFX dose was 387.7 (169.5) mg. During the initial two 
years of IFX administration, mean doses remained between 351 and 402 mg. During 
the initial two years of maintenance IFX administration, the highest observed mean 
dose represented a 15% increase compared to the ﬁrst dose in the maintenance period 
and a 19% increase compared to index dose. Median time between administrations 
was 55 days for all maintenance infusions. CONCLUSIONS: The observed adminis-
tration schedule was consistent with FDA-approved prescribing information. These 
data suggest the IFX dose in patients with RA remained relatively stable and provide 
stakeholders with an understanding of real world utilization.
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DOSES AND INFUSION INTERVALS FOR INFLIXIMAB IN ANTI-TNF 
NAïVE AND ANTI-TNF EXPERIENCED MANAGED CARE PATIENTS 
WITH RHEUMATOID ARTHRITIS
Carter C1, Tang B1, Changolkar A2, McKenzie RS1, Piech CT1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2SOAL PharmaTech Solutions, 
LLC, Phildelphia, PA, USA
OBJECTIVES: To describe inﬂiximab (IFX) doses and infusion intervals in patients 
with RA who are anti-TNF naïve or anti-TNF experienced. METHODS: Medical and 
pharmacy claims for patients ≥18 years with ≥2 RA diagnosis codes received January 
2000-December 2006 were included from a database of commercial health plans. 
Patients were excluded for selected inﬂammatory conditions. Anti-TNF naïve patients 
had no biologic use for 6 months prior to IFX. Anti-TNF experienced patients had 
adalimumab/etanercept prior to IFX. Infused doses were calculated by dividing the 
plan’s allowed amount for each IFX claim by the acquisition cost for a 100 mg vial. 
Results were reported for induction (weeks 0–8), maintenance (weeks 9–52), and 
one-year (weeks 0–52) periods. Infusion intervals included mean time (days) between 
infusions during the ﬁrst year of treatment. RESULTS: A total of 425 naïve (mean 
age = 53 years; 74% female) and 467 experienced (mean age = 49 years; 78% female) 
patients were evaluated. The mean IFX dose per infusion for naïve patients was lower 
during the induction vs. maintenance period (397 mg vs. 455 mg). The mean IFX dose 
per infusion for one year was 437 mg. Nearly all naïve patients (98.5%) received no 
more than 8 infusions in the ﬁrst year. The mean times between IFX infusions for 
naïve patients were 19, 29, 56, 57, 55, 52, and 53 days. The mean IFX dose per 
infusion for experienced patients was lower during the induction vs. maintenance 
period (428 mg vs. 527 mg). The mean times between IFX infusions for experienced 
patients were 18, 28, 52, 50, 49, 48, and 41 days. CONCLUSIONS: This observa-
tional study reveals IFX utilization differences between anti-TNF naïve and experi-
enced patients. Both naïve and experienced patients had infusion intervals within the 
recommended labeling.
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DISPARITIES IN DISEASE MODIFYING ANTI-RHEUMATOID TREATMENT 
IN RHEUMATOID ARTHRITIS
Kawatkar AA1, Nichol MB2
1Kaiser Permanente Southern California, Pasadena, CA, USA, 2University of Southern 
California, Los Angeles, CA, USA
OBJECTIVES: The study objective was to quantify disparities in treatment choice of 
disease modifying anti-rheumatoid drugs (DMARD) used in Rheumatoid Arthritis. 
METHODS: Retrospective cohorts were constructed from California Medicaid paid 
insurance claims between January 1, 1998 to December 31, 2005. Non-overlapping 
monthly episodes were created from pharmacy claims for biologic (adalimumab and 
etanercept) and standard (methotrexate, leﬂuonomide, hydroxychloroquine and sul-
fasalazine) DMARDs. Final sample included 59,788 observations on 7,025 patients. 
Relative risk ratios (RRR) of factors associated with DMARD treatment choice were 
assessed by a multinomial logit model with baseline as methotrexate treatment. 
Covariates included age, gender, race, location of beneﬁciary’s county in either North-
ern or Southern California, population density in beneﬁciaries county, exclusive fee-
for-service reimbursement used in beneﬁciary’s county, Medicare and Medicaid dual 
eligibility, Elixhauser comorbidities index excluding Rheumatoid arthritis, and expen-
ditures associated with pharmacy, out-patient, inpatient, inpatient-MD, LTC, and ER 
visits in the three months prior to treatment. Hypothesis testing was based on cluster 
robust standard errors to control intra-individual correlations. RESULTS: The mean 
age was 58.6 (± 14.5) years with a majority of females (84.0%) and Caucasians 
(37.6%). All the covariates were unbalanced between the six treatment groups. Sta-
tistically signiﬁcant association was observed between choice of DMARD treatment 
and all the covariates. Females were less likely to use sulfasalazine (RRR = 0.64, p < 
0.001), but more likely to use hydroxychloroquine (RRR = 1.45, p = 0.001). The 
elderly patients were less likely to receive biologics as compared to methotrexate. 
Patients residing in high population density locations were more likely to receive 
biologic DMARDs. Hispanics were the only race more likely to receive adalimumab 
(RRR = 1.92, p = 0.001), as compared to Caucasians. CONCLUSIONS: Results 
signify marked evidence of socio-demographic disparity in DMARD treatment for RA, 
and also highlights the variation in DMARD utilization based on geography, and type 
of reimbursement.
PMS70
CONCORDANCE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG 
PRESCRIPTIONS WITH RECENT CLINICAL PRACTICE GUIDELINES IN 
QUEBEC, CANADA
Rahme E1, Roussy JP2, Lafrance JP3, Nedjar H1, Morin S4
1McGill University Health Centre, Montréal, QC, Canada, 2Pﬁzer Canada, Kirkland, QC, 
Canada, 3Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, 4Hôpital Général de 
Montréal, Montréal, QC, Canada
OBJECTIVES: Canadian guidelines for adequate nonsteroidal anti-inﬂammatory drug 
(NSAID) utilisation in patients with gastrointestinal (GI), cardiovascular (CV), con-
gestive heart failure (CHF) and renal risk factors have been recently published. The 
objective is to describe concordance of NSAID utilisation with current clinical practice 
guidelines during two time-periods: April 1, 2005 to March 31, 2007 (post- rofecoxib 
withdrawal period) and April 1, 2002 to March 31, 2004 (pre-rofecoxib withdrawal 
period) in Quebec, Canada. METHODS: Data were obtained from the physician and 
medication claims databases of the Quebec Health Insurance Agency. All prescriptions 
for celecoxib or traditional NSAIDs (tNSAIDs) dispensed to patients 50 years of age 
or older were evaluated for concordance with the guidelines. Prescriptions were strati-
ﬁed by patient GI, CV, CHF and renal risk factors and four risk categories (low, 
moderate, high, and very high) were considered in each condition (GI, CV, CHF and 
renal). RESULTS: Of celecoxib prescriptions, 87.2% were adequate in the post-period 
and 86.5% in the pre-period; while adequate prescriptions for tNSAIDs were 72.6% 
in the post-period and 70.1% in the pre-period. Inadequate prescriptions for celecoxib 
in the post-period were those prescribed to the low GI risk group (10.1%) and to 
either the very high renal risk group (1.3%) or very high CHF risk group (1.7%). In 
the post-period, 4,457 (0.5%) prescriptions of celecoxib in the low or moderate GI 
risk groups received a gastroprotective agent (GPA) co-prescription that was not 
apparently adequate. Among celecoxib prescriptions requiring a GPA co-prescription 
as per recent guidelines, only 30.0% had one that was adequate. Similarly, only 30.0% 
of the tNSAID prescriptions dispensed to those with GI risks received a GPA co-
prescription. CONCLUSIONS: About 87% of celecoxib and 70% of tNSAID pre-
